SLDB - ソリッド・バイオサイエンシズ （Solid Biosciences Inc.）

CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB ), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardan''s 7 th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the … Full story available on Benzinga.com

CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 22 nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 8:00 AM ET.

Solid Biosciences press release (SLDB): Q4 Net loss of $15.2MSolid had $213.7 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2022, compared…

- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement -

CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 3:35 PM ET.

CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 1:40 pm ET.

Solid Biosciences (SLDB) and Phlox Therapeutics entered a strategic collaboration for developing precision medicines for genetic cardiac diseases.The research collaboration will target…

CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The grant was approved by a majority of the independent directors of the Company on January 6, 2023, as an inducement material to Mr. Tan’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (SLDB) appoints a seasoned industry professional, Kevin Tan, CFA, , as CFO.Most recently he served as CFO at Selecta Biosciences.

Solid Biosciences (SLDB) and Phlox Therapeutics entered a strategic collaboration for developing precision medicines for genetic cardiac diseases.The research collaboration will target…

CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The grant was approved by a majority of the independent directors of the Company on January 6, 2023, as an inducement material to Mr. Tan’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (SLDB) appoints a seasoned industry professional, Kevin Tan, CFA, , as CFO.Most recently he served as CFO at Selecta Biosciences.

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer.